Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia by Basile, U. et al.
Contents lists available at ScienceDirect
Journal of Immunological Methods
journal homepage: www.elsevier.com/locate/jim
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia
Umberto Basilea,⁎,1, Mariapaola Marinob,1, Laura Gragnanic, Cecilia Napodanod,⁎,
Francesca Gullie, Krizia Pocinod, Serena Lorinic, Stefano Angelo Santinia, Valerio Basilef,
Luca Mieled, Anna Linda Zignegoc, Gian Ludovico Rapaccinid
a Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Università Cattolica del Sacro Cuore, Rome, Italy
b Istituto di Patologia generale, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Università Cattolica del Sacro Cuore, Rome, Italy
c Interdepartmental Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, and Department of Oncology,
Azienda Ospedaliero-Universitaria Careggi (AOUC), Florence, Italy
dDipartimento di Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Università Cattolica del Sacro Cuore, Rome, Italy
e Dipartimento di Medicina di Laboratorio, Ospedale Madre Giuseppina Vannini, Rome, Italy
fDipartimento di Medicina di Laboratorio, Università di Tor Vergata, Rome, Italy





Vascular endothelial growth factor
Biomarkers
A B S T R A C T
Background: Infections, autoimmunity and cancer play a role as determinants of etiology in Hepatitis C virus
(HCV) related mixed cryoglobulinemia (MC). Several factors of risk have been suggested as markers of patho-
genesis and progression of HCV-related MC into B cell Non-Hodgkin's Lymphoma (B-NHL). Here, we evaluated
IgG subclass distribution, free light chains (FLCs) and vascular endothelial growth factor (VEGF) as a new
combination of biomarkers.
Methods: We measured IgG1–4 subclasses, FLCs and VEGF levels in sera 53 from HCV-related MC, in comparison
with 40 sera from HCV negative patients with rheumatoid arthritis (RA) and 30 from healthy blood donors
(HBD).
Results: IgG3 levels were significantly higher in HCV-MC patients with a decrement of IgG2 and IgG4; FLC levels
significantly increased in both MC and RA patients' groups; serological VEGF was higher in HCV-MC patients
than in HBD in correlation with k and λ levels.
Conclusion: Our results suggest that a specific IgG subclasses pattern together with raised levels of FLCs and
VEGF could represent the biomarker “signature” of an inflammation multistage of acquired immune system.
1. Introduction
Chronic Hepatitis C virus (HCV) infection leads to the frequent as-
sociation between liver and extrahepatic disorders. HCV tropism for
lymphoid cells may contribute to poly-oligoclonal B-lymphocyte ex-
pansion causing the production of different autoantibodies and im-
munocomplexes, such as mixed cryoglobulins (CGs) that are commonly
observed in a high proportion of patients with HCV infection (Zignego
et al., 2017).
Mixed cryoglobulinemia (MC) consists in a systemic vasculitis
characterized by the deposition of immunocomplexes composed of
HCV, anti-HCV polyclonal IgG, and monoclonal (type II) or polyclonal
(type III) IgM with rheumatoid factor (RF) activity.
Infections, autoimmunity and cancer have been implicated as de-
terminants of etiology in MC however; HCV is the most frequent in-
fectious trigger (Gulli et al., 2017, Basile et al., 2018a, 2018b).
Due to the complex virus-host interactions, MC represents an ex-
cellent model to investigate the pathogenetic mechanisms of HCV in-
fection and its evolution into autoimmune/lymphoproliferative dis-
orders that are still poorly understood (Basile et al., 2018a, 2018b). The
clinical spectrum of MC is extremely wide, ranging from completely
asymptomatic forms without vasculitis to life-threatening
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complications; the worsening evolution into B cell Non-Hodgkin's
Lymphoma (B-NHL) occurs in about 10% of cases (Ramos-Casals et al.,
2012).
Human IgG class includes four subclasses (IgG1–4), highly con-
served, that differ in their constant region, particularly in their hinges
and upper CH2 domains. Although they are> 90% identical on the
amino acid level, each subclass has a unique profile with respect to
antigen binding, immunocomplexes formation, complement activation,
triggering of effector cells, half-life, and placental transport. Differences
in structure at the hinge region, where the Fab section bends and ro-
tates with respect to the Fc section determines the differential ability to
bind their target; the flexibility at the hinge is greatest in IgG3 (Sigal,
2012). Only recently, a different IgG subclasses distribution in serum
between patients with autoimmune diseases and healthy controls has
been described, with distinct patterns in different conditions (Zhang
et al., 2015). A higher prevalence of IgG3 subclass in responses to HCV
antigens seems to be more frequent in those patients who are HCV- and
MC-positive, rather than in patients who are HCV-positive and MC-
negative (Basile et al., 2017a, 2017b, Dispenzieri and Gorevic, 1999).
Human and murine IgG3 display an equivalent tendency to self-as-
semble, although there are structural and functional differences, de-
monstrating a role in the molecular mechanism of the formation of
cryoprecipitate (Otani et al., 2012; Izui et al., 1993). In the years, the
study and characterization of human CGs in patients with HCV infec-
tion showed a prevalent abundance of IgG3 in cryoprecipitates sug-
gesting that the immune system is highly stimulated and more prone to
the development of autoimmune disorders, supporting the hypothesis
of a specific involvement of IgG3 subclass as an early trigger of CGs
(Basile et al., 2017a, 2017b). Recently, we reported the evidence of CGs
exclusively composed of IgG1 and IgG3 with RF activity, maybe re-
presenting an early stage of MC (Gulli et al., 2018). Immunoglobulin-
(Ig-) free light chains (FLCs) are bioactive molecules (Basile et al.,
2017b) produced during the synthesis of immunoglobulins. Due to their
fast turnover, particularly for the k chain (< 6 h compared to
20–25 days to total IgG), and in subjects with normal kidney function,
serum levels could be considered as a direct marker of B-cell activity,
which is otherwise difficult to measure in routine clinical practice.
Different reports and guidelines demonstrated the relevance of ser-
ological FLC levels in the diagnostic and prognosis pathway of diseases
caused by deposition of immunocomplexes and immune-proliferative
disorders, and for monitoring the therapeutic outcomes (Basile et al.,
2017b; Charafeddine et al., 2012; Graziani and Merlini, 2014). A ser-
ological increase of polyclonal FLC may help to identify individuals at
higher risk of developing a monoclonal gammopathy. Moreover, poly-
clonal increments may anticipate the development of MGUS, suggesting
their role as determinant of pathogenesis (Kumar et al., 2019). The
assessment of FLCs and the k/λ ratio in patients with HCV infection
may be clinically useful especially for predicting the onset of MC.
Terrier and co-workers described high levels of free k chains in HCV-
positive patients with MC and type II MC (Terrier et al., 2009). An
abnormal k/λ ratio may be useful to predict response to biological
drugs that represent an expensive treatment for patients with HCV-re-
lated MC (Basile et al., 2015).
Vascular endothelial growth factor (VEGF) represents a primary
driving force for both physiological and pathological angiogenesis, and
raised circulating VEGF levels have been described in lymphoproli-
ferative disorders as multiple myeloma (MM), chronic myeloid leu-
kemia, chronic myelomonocytic leukemia, chronic lymphocytic leu-
kemia, and lymphoma, often in correlation with disease activity (Pihan
et al., 2018; Villani et al., 2016). VEGF plays a vital role in the pro-
gression of NHL and a systemic meta-analysis study showed that the
overexpression of VEGF in lymphoma tissue represents a promising
potential prognostic factor in NHL (Yang et al., 2015). The fibrogenic
effect of VEGF through multiple mechanisms is well known, including
the promotion of inflammation, and the release of fibrosis enhancing
molecules (Lee et al., 2004; Yoshiji et al., 2003). Of note, serum VEGF
levels are significantly increased also in patients with systemic auto-
immune rheumatic diseases (SARD) (Choi et al., 2003) with serological
levels correlated to disease severity and clinical complications
(Hashimoto et al., 2003).
In this study, we measured the serological levels of IgG subclasses,
FLCs, and VEGF in 53 HCV-related MC patients compared to 40 HCV-
negative patients with active RA and to healthy blood donors (HBD).
Our aim was to verify if this new combination of biomarkers may be
useful to evaluate the progression of inflammation stage.
2. Materials and methods
2.1. Patients and controls
Ninety-three patients with chronic diseases were retrospectively
enrolled including 53 HCV related MC (median age 60.4 ± 1.7 years)
and 40 HCV-negative patients with RA (median age 62 ± 5.0 years);
30 HBD (median age 60 ± 7.2 years) were used as negative controls.
Patients were enrolled at two Italian centers (Center for Systemic
Manifestations of Hepatitis Viruses (MaSVE), Department of
Experimental and Clinical Medicine, University of Florence, Florence;
Fondazione Policlinico Agostino Gemelli- I.R.C.C.S, Università Cattolica
del Sacro Cuore, Rome). The main demographic, clinical, and vir-
ological characteristics of the study population are reported in Table 1.
HCV-related MC patients were included in the study according to
the following criteria: presence of HCV-RNA in serum; positivity for
type II CG; absence of antiviral treatment and/or immunosuppressive
therapy; presence of MC symptoms, according to the classification cri-
teria for MC as proposed by the Italian Group for the Study of
Cryoglobulinemias in 1989 and later revised in 2002 (Ferri et al.,
2002).
Transient elastography represents a very useful and advantageous
diagnostic tool because it can be performed repeatedly, does not require
a highly experienced operator, and has a low risk of complications.
Measurements of liver stiffness with transient elastography in these
patients are well correlated with fibrosis METAVIR stages.
The inclusion criteria for the 40 HCV-negative RA patients were
represented by absence of radiologically visible lesions, absence of
therapy, presence of a high level of anti-cyclic citrullinated peptide,
positivity for rheumatoid factor.
All patients had a normal renal function with an estimated
Table 1
Demographic, clinical, and virological features correlates of HCV-related
MC patient.
MC Patients(n=53)







Child Pugh-score (A/B/C) 28/2/0
ALT (U/L) 120.4 (±10)
AST (U/L) 94 (±8)
Total Bilirubin (mg/dL) 0.94 (± 0.05)
Direct Bilirubin (mg/dL) 0.32 (± 0.02)







Cryocrit (%) 4.2 (± 0.2)
RF (UI/mL) 30.5 (± 1.7)
C4 (mg/dL) 0.15 (± 0.02)
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glomerular filtration rate of ≥60mL/min/1.73m2.
The whole study was conducted according to the Declaration of
Helsinki and approved by the Ethical Committee at the Università
Cattolica; all the participants provided written informed consent prior
to enrollment. All samples were processed anonymously.
2.2. Laboratory testing
Sera were obtained by standard centrifugation, divided into aliquots
and stored frozen until analysis. Samples were thawed only once and
immediately assayed in a blinded fashion and in a single batch. FLCs
were assessed using the Freelite™ Human Kappa and Lambda Free Kits
(The Binding Site, Birmingham, UK) on an Optilite instrument (The
Binding Site, Birmingham, UK; free κ normal range: 3.3–19.4 mg/L; free
λ normal range: 5.7–26.3 mg/L). A ratio of k/λ<0.26 or > 1.65 is
abnormal, according to the manufacturer's recommendations.
The four IgG subclasses concentrations were measured by turbidi-
metry through the employment of Human IgG and IgG subclass liquid
reagent kits (The Binding Site Birmingham, UK) with Optilite instru-
ment according to the manufacturer's recommendations. These kits are
intended for quantifying human IgG and IgG subclasses. Concentrations
are automatically calculated by reference to a standard curve stored
within the instrument. Normal range for subclasses: 3.82–9.29 g/L for
IgG1; 2.42–7.0 g/L for IgG2; 0.22–1.76 g/L for IgG3; 0.04–0.86 g/L for
IgG4.
Samples were tested according to the manufacturer's instructions
and serum dilutions, where necessary, were performed according to the
manufacturer's recommendations.
Assessment of serum VEGF levels was performed through the en-
zyme-linked immunosorbent assay (ELISA) employing monoclonal an-
tihuman VEGF antibodies (R&D System, Minneapolis, MN, USA). The
detectable concentration ranges were 31.2–2000 pg/mL for VEGF.
Anti-cyclic Citrullinated Peptide and rheumatoid factor were de-
tected through a magnetic microparticle based method using chemilu-
minescent detection (acridinium) to provide a high degree of precision
and rapidity of analysis (Menarini Diagnostics Zenit, Bologna, Italy).
Samples were tested according to the manufacturer's instructions and
serum dilutions, where necessary, were performed according to the
manufacturer's recommendations.
HCV-RNA was assessed in both supernatant and cryoprecipitate and
was determined through real-time polymerase chain reaction, tran-
scription-mediated amplification, and multi-probe reverse hybridiza-
tion of the 5′ untranslated region of the HCV genome. The HCV geno-
type was determined for each sample by using the line probe assay
Versant HCV genotype LiPA 2.0 (Siemens Healthcare Diagnostics,
Munich, Germany). Genotypes and subtypes detectable from this test
include 1, 1a, 1b, 2, 2a/2c, 2b, 3, 3a, 3b, 3c, 4, 4a, 4b, 4c/4d, 4e, 4f, 4 h,
5a, and 6a.
All the determinations were performed by an operator without
knowledge of the clinical information of the handled sample. Each
sample was tested twice to minimize eventual discrepancies, and all
tests were performed in the same laboratory with the same instruments.
All safety precautions were taken while handling potentially harmful
samples.
2.3. Statistical analysis
Comparison of mean values was performed by Student's t-test; p
values< .05 were considered significant. A correlation analysis was
carried out using the Pearson correlation coefficient.
3. Results
3.1. Serological IgG subclasses distribution among HCV-related MC, RA-
patients and HBD
The mean values (± standard deviation) of IgG subclasses are re-
ported in Table 2 and displayed in Fig. 1A. Only in HCV-related MC
patients, serum IgG subclasses showed a significantly different dis-
tribution from HBD even if the mean values were within the normal
range. In particular, IgG3 were higher in HCV patients than in HBD
(1.01 ± 0.42 g/L vs 0.68 ± 0.33 g/L, p < .01); on the contrary, IgG2
and IgG4 were lower in HCV-positive patients if compared to HBD
(IgG2: 2.77 ± 1.44 g/L in HCV vs 4.00 ± 1.38 g/L in HBD, p < .05;
IgG4: 0.31 ± 0.20 g/L in HCV vs 0.61 ± 0.58 g/L in HBD, p < .01).
3.2. Serological FLCs levels in HCV-related MC, RA-patients and HBD
The mean values (± standard deviation) of FCLs and k/λ ratio are
reported in Table 3 and visualized in Fig. 1B. The statistical analysis
revealed significant differences between patients and HBD. The mean
values of k and λ free chain levels were significantly higher in both
patients' groups (HCV-MC k and λ: 25.94 ± 11.54mg/L and
34.63 ± 20.44mg/L, respectively; RA k and λ: 35.89 ± 35.87mg/L
and 22.58 ± 23.90mg/L, respectively) if compared to HBD (HBD k:
8.88 ± 3.86mg/L, HBD λ: 12.90 ± 7.05mg/L). FLCs mean values
were above the positivity cut-off for HCV-MC patients while in RA free
λ mean value was still within the normal range (as determined by the
manufacturer); for this reason, the k/λ ratio was significantly higher
only in RA patients when compared to HBD (1.73 ± 0.59 vs
0.75 ± 0.21, respectively).
3.3. Serum VEGF assessment in HCV-related MC patients and HBD
The mean value of VEGF in HCV-related MC patients was higher and
statistically more significant than in HBD (441.78 ± 185.78 pg/mL vs
64.85 ± 29.45 pg/mL, p < .01), as shown in Fig. 1C. We evaluated if
VEGF correlated with FLCs levels in MC patients. We found that VEGF
displayed a correlation with both free chains that was strong with free k
(R=0.706383828) and moderate with free λ (R=0.52102002)
(Fig. 1D).
4. Discussion
HCV driven autoimmune and lymphoproliferative disorders are the
consequence of a multifactorial and multistep pathogenetic process and
HCV-related MC represents the prototype of a complex intersection
between autoimmunity and neoplastic disorders (Saadoun et al., 2007).
Because CGs producing B-cells in the course of HCV infection are mostly
monoclonal, HCV-related MC can be considered a benign B-cell lym-
phoproliferative condition. The overall risk of non-Hodgkin's
Table 2
IgG subclasses distribution in patients and controls.
HCV RA HBD
IgG1(g/L) 7.34 ± 2.91 8.71 ± 4.48 7.00 ± 1.62
IgG2(g/L) 2.77 ± 1.44⁎ 4.07 ± 2.20 4.00 ± 1.38
IgG3(g/L) 1.01 ± 0.42⁎⁎ 0.88 ± 0.54 0.68 ± 0.33
IgG4(g/L) 0.31 ± 0.20⁎⁎ 0.55 ± 0.47 0.61 ± 0.58
MC: mixed cryoglobulinemia. RA: rheumatoid arthritis. HBD: healthy blood
donors.
Data are expressed as mean ± standard error.
Normal range for subclasses: 3.82–9.29 g/L for IgG1; 2.42–7.0 g/L for IgG2;
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lymphoma in patients with HCV-MC is estimated to be 35 times higher
than in the general population (Gulli et al., 2017). The mechanisms
underlying the development of HCV-related B-cell lymphoma remain to
be elucidated. Until now, limited data concerning a direct infection of
B-cells in HCV-associated B-cell lymphoma are reported in literature
(Levine et al., 2003). Alternatively, HCV can exert its oncogenic po-
tential indirectly through chronic stimulation on the immune system,
leading to the selection of abnormal B clones.
Viral infections usually lead to the increase of IgG1 and IgG3
subclasses, with the IgG3 switching first appearing during the anti-viral
immune response. In a previous paper, by the employment of im-
munofixation, we reported that IgG3 monoclonal CGs with RF activity
induced extensive extra-hepatic manifestations in HCV patients (Basile
et al., 2017a, 2017b, Basile et al., 2018b). In the present study, we
confirmed our results on IgG3 subclass as initial trigger of CGs forma-
tion by using a turbidimetric assay that allows the quantification of
human IgG subclasses. The measurement of IgG subclasses is a valuable
tool in the diagnosis of abnormal protein metabolism and immune
Fig. 1. Distribution of IgG Subclasses, FLC and VEGF in patients and control group.
A: Serum IgG subclasses levels in HCV-MC, RA-patients and HBD. *= p (HCV-MC vs HBD) < 0.05; **= p (HCV vs HBD) < 0.01B: Free light chains levels in HCV-
MC, RA-patients and HBD, *= p (patients vs HBD) < 0.05; **= p (patients vs HBD) < 0.01.C: Serum VEGF levels in HCV-MC patients and HBD, p < .01. D:
Correlation between k and λ levels and VEGF in HCV-MC patients.
Table 3
k, λ and k/λ ratio mean values in patients and controls.
κfree (mg/L) λfree(mg/L) κ/λ
HCV 25.94 ± 11.54 (p < .01) 34.63 ± 20.44 (p < .01) 0.87 ± 0.35 (NS)
RA 35.89 ± 35.87 (p < .01) 22.58 ± 23.90 (p < .05) 1.73 ± 0.59 (p < .01)
HBD 8.88 ± 3.86 12.90 ± 7.05 0.75 ± 0.21
MC: mixed cryoglobulinemia. RA: rheumatoid arthritis. HBD: healthy blood donors. NS: Not Significant.
Data are expressed as mean ± standard error;
Normal range for FLCs: 3.30–19.40mg/L for k; 5.71–26.30mg/L for λ. A ratio of k/λ<0.26 or > 1.65 is abnormal;
p was calculated between each patient group and HBD.
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system's lack ability to face infectious agents. Moreover, we explored
the serological concentration distribution of Ig subclasses in 53 HCV-
related MC patients in comparison to 40 HCV negative patients with a
systemic autoimmune disorder such as RA and with 30 HBD. We found
that levels of serum IgG3 subclass were higher in HCV-MC patients than
in RA and HBD (in the latter case, with a statistically significant dif-
ference), confirming our previous observation about high presence of
IgG3 in cryoprecipitate (Basile et al., 2017a, 2017b). The different
profile of IgG subclasses distribution that we found in HCV-MC could
reflect a different immune response depending on the specific auto-
antigen and time of stimulation. The evidence of an association with a
specific IgG subset increase was crucial to the identification of IgG4-
related diseases. However, the possibility of other associations between
autoimmune diseases and IgG subclasses are still less investigated
(Kamisawa et al., 2015). It is also conceivable that, for the same IgG
subclass, different cut-offs may be considered for different diseases.
Our results strengthen the hypothesis that IgG3 subclass increase
represents the first alert step towards the pathogenesis of CGs and au-
toimmune response in these patients. Subsequently early intervention
of FLC at the initial phase might modify natural history of the disease in
a negative way. This is likely to lead to screening approach and iden-
tification of early state of CGs in the population with HCV infection
(Fig. 2A) (Basile et al., 2017a, 2017b).
The synthesis of antibodies is accompanied by an excess of light
chain production giving rise to a release of about 500mg/day of
polyclonal FLC in the peripheral circulation (Basile et al., 2017b). This
production is abnormally higher in several pathological autoimmune
conditions reflecting B-cell activation and giving insight into the ac-
tivity of the adaptive immune system. Particularly, FLCs may represent
a marker of overall B-cell activity in those diseases where there is an
increase of autoantibodies and immune complexes such as SARD
(Napodano et al., 2019). In these conditions, characterized by chronic
inflammatory reactions, FLCs may play a pathogenetic role. Owing to
their short half-life, FLC quantitative analysis has become a useful di-
agnostic tool to measure B clonal expansion in plasma cell dyscrasias.
Specific FLC patterns were also associated with the presence of MC
vasculitis and/or B-NHL in HCV-positive patients with an interesting
correlation to antiviral therapy response (Geri et al., 2010). Clinical
interest in the determination of FLCs in viral infections (human im-
munodeficiency virus or hepatitis C virus) derives from their putative
role as an early biomarker of tumor onset, especially lymphoma (Bibas
et al., 2012). MC and B-NHL represent the main extrahepatic manifes-
tations of HCV (Gragnani et al., 2015) and serum levels of FLCs have
recently been used as marker of worsening progression (Oliveira et al.,
2014). In a previous report, analyzing a group of HCV-positive patients
with/without MC, we clearly confirmed the role of FLC as a serum
biomarker of disease activity, and of rituximab therapy response (Basile
et al., 2015). In the present study, we analyzed the FLC serological
profile in a larger group of HCV-MC patients in comparison to HCV-
negative patients with RA, a systemic autoimmune disorder char-
acterized by a strong elevation of circulating FLCs levels. Our results
confirm that HCV-related MC is strongly associated with high levels of
FLCs comparable to RA, underlying the strong correlation with B-cell
hyperactivity in both diseases. Specific FLC patterns were also asso-
ciated with MC vasculitis and/or B-NHL in HCV-positive patients with
an interesting correlation to antiviral therapy response (Gragnani et al.,
2015; Geri et al., 2010). We hypothesize that following HCV exposure,
B-lymphocytes could be activated to produce complete Ig, and poly-
clonal FLCs. FLCs could bind B cell surface through a still unknown
receptor and become “key” mediators of the inflammatory response
(Fig. 2B).
Extrahepatic manifestations in HCV-positive patients involve mul-
tiple organ systems with a variety of comorbidities, which may lead to
significantly increased mortality rate. VEGF is the most important
Fig. 2. Activation of innate immunity. A: the prolonged stimulation of the immune system, during the inflammatory process, can lead to hyperstimulation of plasma
cells and polyclonal activation of B cells. Activated B cells differentiate into plasma cells and produce IgG3 autoantibodies directed against tissue and im-
munoglobulin autoepitopes. IgG3 subclass is involved in the initiation of the early stages of CGs. The overproduction of plasma cells causes a considerable increase of
the polyclonal Free Light Chains (FLC) concentration, which could be responsible for further cell activation. B: FLCs through the binding of a B cell surface, still
unknown, receptor (*) could mediate the inflammatory respon.
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determining factor for both physiological and pathological angiogen-
esis. It plays an important role in the induction of neovascularization in
solid cancers contributing to the invasive ability of liver tumors, espe-
cially of hepatocellular carcinoma (Lee et al., 2004, Clauss, 2000,
Mukozu et al., 2013); raised levels of VEGF have been described also in
different hematologic malignancies. Hashimoto and co-workers showed
its increase in SARD patients with serum levels correlated with disease
severity and the presence of complications. Here, we analyzed VEGF
serological levels in HCV-related MC patients: we found that not only it
was higher and statistically more significant than HBD
(441.78 ± 185.78 pg/mL vs 64.85 ± 29.45 pg/mL), but also higher if
compared to the mean value described for RA patients (359 ± 94 pg/
mL by Hashimoto and coworkers) (Hashimoto et al., 2003). Moreover,
the finding of a positive correlation of raised VEGF levels with both k
and λ FLCs in HCV-MC patients could be suggestive that the strong
viral-driven B activation would be worsening into lymphoproliferative
disorders (Fig. 1D).
In conclusion, our main goal is to identify a biomarker profile that
could be very helpful in patients' management and as screening test, for
setting diagnosis and classification of patients with HCV-related MC.
Precision medicine approach is the start of routine care for most pa-
tients. Based on our results, we suggest that the worsening progression
of disease towards extrahepatic manifestations could be monitored with
specific IgG profile together with increased serological levels of FLCs
and VEGF. Following further validation, their employment in new in-
tegrated specific diagnostic panels will represent the main challenge of
clinical and laboratory investigations. Further studies will be useful to
better clarify the role of VEGF and FLC in the inflammatory multi-sta-
dial progression in lymphoma.
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